Shares of ABIVAX climbed around 9 percent in the morning trading in Paris after the biotechnology company focused on HIV, inflammatory/autoimmune diseases and cancer, announced Tuesday positive top line data for the second cohort of the ABX464-005 phase 2a study in HIV infection.
In a statement, the company noted that study ABX464-005, a Phase 2a clinical trial, aims at studying the effects of ABX464 on HIV DNA (HIV reservoir) in blood and in rectal tissue in fully suppressed HIV patients.
The study was conducted at the Germans Trias i Pujol University Hospital Badalona in Spain. For the first time, data were available from rectal tissue biopsies.
Jean-Marc Steens, Chief Medical Officer at ABIVAX, said, "These findings show, for the first time, that ABX464 has the ability to reduce HIV DNA in both blood and rectal tissue reservoirs. The longer 12 week duration of treatment with ABX464 was safe and generally well tolerated and supports extended dosing."
The Phase 2a clinical study with ABX464 in Ulcerative Colitis is fully enrolled, with last patients having their last visit this month. Top line data is expected to be available in the fall of this year.
In Paris, Abivax shares were trading at 7.41 euros, up 9.3 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.